Clinical Practice Session
AKI in Cirrhosis: Will Personalized Management Improve Outcomes?
November 04, 2022 | 04:30 PM - 06:00 PM
Location: W224, Orange County Convention Center, West Building
Session Description
Patients with AKI with cirrhosis, including hepatorenal syndrome (HRS), experience poor outcomes. Therapies for HRS include volume expansion with IV albumin, with or without vasoconstrictors. However, clinical outcomes remain poor in HRS, and adverse drug events are possible. This session reviews the pathogenesis of HRS and the use of IV albumin and vasoconstrictors (including terlipressin). Discussion includes how improved phenotyping using markers of volume status, kidney function, and kidney damage may help clinicians target therapy and optimize outcomes.
Learning Objective(s)
- Describe the current understanding of the pathophysiology and underlying causes of HRS
- Explain the rationale, recommended use, and clinical outcomes of therapy with IV albumin in patients with cirrhosis and AKI
- Discuss current evidence concerning the use of vasoconstrictor therapy in patients with HRS
- Discuss diagnostic tools to characterize the underlying cause of AKI in patients with cirrhosis, to target therapy, and to optimize clinical outcomes
Learning Pathway(s)
- AKI and Critical Care
- Pharmacology
Moderators
- Jean Maxime Cote, MD, MSc
- Ashita J. Tolwani, MD, MS, MSc
Presentations
- Pathogenesis of Hepatorenal Syndrome
04:30 PM - 04:50 PM
Juan Carlos Q. Velez, MD, FASN
- Albumin Therapy in Cirrhosis: Too Much of a Good Thing?
04:50 PM - 05:10 PM
Andrew S. Allegretti, MD, MS
- Vasoconstrictor Therapy in Hepatorenal Syndrome: What Is the Evidence?
05:10 PM - 05:30 PM
Mitra K. Nadim, MD, FASN
- AKI Biomarkers in Patients with Cirrhosis: Can Improved Phenotyping Guide Better Therapy?
05:30 PM - 05:50 PM
Justin Miles Belcher, MD, PhD
- Q&A
05:50 PM - 06:00 PM
